BEAM
Beam Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$29.66
+0.68%Sep 2, 2026, 06:02 UTC
Beam Therapeutics appointed Eric Foster as chief commercial officer.
Source:Aug 4, 2026, 13:26 UTC
Beam Therapeutics Inc. reported a second-quarter loss of $1.18 per share, missing the Zacks Consensus Estimate of a loss of $1.00 per share.
Jul 8, 2026, 12:00 UTC
Prime Medicine announced a positive binding resolution of its arbitration with Beam Therapeutics, with the tribunal declaring PM647 within Prime Medicine's field and no monetary damages owed.
Jun 18, 2026, 11:00 UTC
The U.S. FDA cleared Beam Therapeutics' IND application for BEAM-304 for the treatment of phenylketonuria.
Source: